MA53607A - (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés - Google Patents

(r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés

Info

Publication number
MA53607A
MA53607A MA053607A MA53607A MA53607A MA 53607 A MA53607 A MA 53607A MA 053607 A MA053607 A MA 053607A MA 53607 A MA53607 A MA 53607A MA 53607 A MA53607 A MA 53607A
Authority
MA
Morocco
Prior art keywords
carbamoylpyridin
trifluoromethoxy
piperazine
carboxylate
benzyl
Prior art date
Application number
MA053607A
Other languages
English (en)
Inventor
Lianfeng Huang
Nancy Tsou
Nicole Suzanne White
Jun Xu
Qun Zhang
Original Assignee
Abide Therapeutics Inc
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc, Celgene Corp filed Critical Abide Therapeutics Inc
Publication of MA53607A publication Critical patent/MA53607A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053607A 2018-09-13 2019-09-12 (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés MA53607A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862731014P 2018-09-13 2018-09-13

Publications (1)

Publication Number Publication Date
MA53607A true MA53607A (fr) 2021-12-22

Family

ID=68069873

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053607A MA53607A (fr) 2018-09-13 2019-09-12 (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés

Country Status (21)

Country Link
US (3) US11053199B2 (fr)
EP (2) EP3849970B1 (fr)
JP (1) JP7405840B2 (fr)
KR (1) KR20210057789A (fr)
CN (3) CN118561814A (fr)
AU (1) AU2019337623A1 (fr)
BR (1) BR112021004340A2 (fr)
CA (1) CA3112200A1 (fr)
CL (1) CL2021000596A1 (fr)
CO (1) CO2021003295A2 (fr)
DK (1) DK3849970T3 (fr)
EA (1) EA202190511A1 (fr)
FI (1) FI3849970T3 (fr)
IL (1) IL281276B1 (fr)
LT (1) LT3849970T (fr)
MA (1) MA53607A (fr)
MX (1) MX2021002923A (fr)
PT (1) PT3849970T (fr)
RS (1) RS65967B1 (fr)
SG (1) SG11202102143RA (fr)
WO (1) WO2020056105A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849773B1 (fr) * 2005-02-17 2013-10-16 Astellas Pharma Inc. Dérivés de piperazine pour le traitement de l'incontinence unrinaire et la douleur
JP2017505777A (ja) * 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
EP3595665B1 (fr) 2017-03-13 2024-08-28 Lundbeck La Jolla Research Center, Inc. Inhibiteurs doubles de magl et de faah

Also Published As

Publication number Publication date
US20200095201A1 (en) 2020-03-26
EP3849970A1 (fr) 2021-07-21
IL281276A (en) 2021-04-29
EP3849970B1 (fr) 2024-07-03
DK3849970T3 (da) 2024-09-30
AU2019337623A1 (en) 2021-05-13
CN118561814A (zh) 2024-08-30
JP2022500441A (ja) 2022-01-04
IL281276B1 (en) 2024-09-01
JP7405840B2 (ja) 2023-12-26
US20210363105A1 (en) 2021-11-25
CA3112200A1 (fr) 2020-03-19
PT3849970T (pt) 2024-09-25
BR112021004340A2 (pt) 2021-05-25
CO2021003295A2 (es) 2021-07-30
US11680046B2 (en) 2023-06-20
CN113227069A (zh) 2021-08-06
CN113227069B (zh) 2024-11-05
KR20210057789A (ko) 2021-05-21
RS65967B1 (sr) 2024-10-31
US20230382861A1 (en) 2023-11-30
MX2021002923A (es) 2021-09-08
WO2020056105A9 (fr) 2020-07-09
WO2020056105A1 (fr) 2020-03-19
SG11202102143RA (en) 2021-04-29
EP4434583A2 (fr) 2024-09-25
US11053199B2 (en) 2021-07-06
FI3849970T3 (fi) 2024-09-20
CL2021000596A1 (es) 2021-07-30
CN118530218A (zh) 2024-08-23
EA202190511A1 (ru) 2021-07-05
LT3849970T (lt) 2024-10-10

Similar Documents

Publication Publication Date Title
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA53235A (fr) Indoles substitués et procédés d'utilisation associés
DK3864152T5 (da) Fremgangsmåder og sammensætninger til editering af rna'er
MA54875A (fr) Compositions oligonucléotidiques et procédés associés
MA46389A (fr) Variants de l'endonucléase homing pd1, compositions et procédés d'utilisation
MA48797A (fr) Variants de l'endonucléase cblb , compositions et procédés d'utilisation
MA52134A (fr) Compositions et procédés pour l'édition génomique
MA52797A (fr) Inhibiteurs de masp -2 et procédés d'utilisation
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA53239A (fr) Procédés d'administration de certains inhibiteurs de vmat2
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA55079A (fr) Composition et récipient, kit, procédé d'utilisation
EA202190356A1 (ru) Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов
MA50433A (fr) Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité
DK3979827T3 (da) Næringssammensætning omfattende 2'fucosyllactose og 3'galactosyllactose
IL286164A (en) -(2-bromo-4-alkynyl-6-alkoxyphenyl)-3-pyrroline-2-ones and their use as herbicides
MA53167A (fr) Récepteurs chimériques de steap1 et procédés d'utilisation associées
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
EP4074711A4 (fr) Inhibiteur de l'autotaxine hétérocyclique contenant de l'azote, composition le contenant et son utilisation
MA56069A (fr) Composition herbicide
MA55532A (fr) Composés de neuréguline-4 et procédés d'utilisation
MA53391A (fr) Compositions pour l'agriculture et procédés associés